India, Feb. 10 -- Shares of Delcath Systems Inc. (DCTH) touched a new 52-week high of $16.97 last week, and that reflects a gain of over 100% in less than 6 months.
This interventional oncology company, focused on the treatment of primary and metastatic cancers of the liver, markets HEPZATO KIT, a drug/device combination product, which is comprised of the chemotherapeutic drug Melphalan and Delcath's proprietary Hepatic Delivery System (HDS).
In the U.S., HEPZATO KIT was approved by the FDA in August 2023 as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcuta...